Amicus Therapeutics US's annual revenues are $100-$500 million (see exact revenue data) and has 100-500 employees. It is classified as operating in the Scientific Research & Development Services industry.
Note: Amicus Therapeutics US's revenues are gauged from an analysis of company filings.
Amicus Therapeutics US has actively raised capital from investors. These investors may include private investors, venture capital firms, or other investment vehicles.
July 19, 2016
Complete list of funding rounds and total amounts in the Company Report
Trademark applications show the products and services that Amicus Therapeutics US is developing and marketing.
Amicus Therapeutics US's new tradmarks suggest it is investing in R&D and marketing, while expanding into new products or markets.
Trademarks may include brand names, product names, logos and slogans.
POMBILITI Pharmaceutical preparations for the treatment of Pompe disease; Pharmaceutical preparations for the treatment of genetic diseases
UPOMVI Pharmaceutical preparations for the treatment of Pompe disease; Pharmaceutical preparations for the treatment of genetic diseases
RENJOZY Pharmaceutical preparations for the treatment of Pompe disease; Pharmaceutical preparations for the treatment of genetic diseases
Determine whether Amicus Therapeutics US grew or shrank during the last recession. This is useful in estimating the
financial strength and credit risk of the company.
Compare how recession-proof Amicus Therapeutics US is relative to the industry overall.
While a new recession may strike a particular industry, measuring the
industry and company's robustness during the last recession estimates its ability to weather future recessions.
Market Share of Amicus Therapeutics US's Largest Competitors
A competitive analysis shows these companies are in the same general field as Amicus Therapeutics US, even though they may not compete head-to-head.
These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines.
The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies.
Competitive advantage comes from offering better pricing or superior products/service.
These companies are similar in business line and location to Amicus Therapeutics US.
While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.
These companies are in the same general field as Amicus Therapeutics US and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.